1. Pink Sheet
  2. >>Market Access

Medicare Drug Pricing Casts A Cloud Over J.P. Morgan’s Opening Day

 
• By Jessica Merrill

Inflation Reduction Act means that industry ‘will have to adjust’ to new market realities, especially for small molecule drugs.

J.P. Morgan Policy Notes
• Source: Shutterstock

SAN FRANCISCO—Policies under the Inflation Reduction Act (IRA) that will allow Medicare to negotiate drug prices have been an overhang for the otherwise celebratory start of the J.P. Morgan Healthcare Conference. The IRA is expected to be a hot topic at the meeting, with one of the keynote spots dedicated to the new law’s impact on innovation.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Pink Sheet Podcast: Vaccine Review Political Interference, Missed Deadlines A Harbinger Of US FDA Problems?

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors discuss FDA Commissioner Martin Makary’s decision to have one of his assistants lead negotiations for Novavax’s delayed COVID-19 vaccine review, as well as some recent missed review deadlines, which may be the result of recent FDA cuts.

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

EU ‘Can’t Expect Industry To Give Up Proprietary Insights’ Under Health Data & Clinical Trials Regulations

 
• By Eliza Slawther

Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.